ACP-501
Phase 1- Indications
- Coronary heart disease, Familial LCAT deficiency
Company intelligence / Profile preview
AlphaCore Pharma
Ann Arbor, Michigan, United Statesnhlbi.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
AlphaCore Pharma developed ACP‑501, a recombinant human LCAT therapy. The company aimed to treat familial LCAT deficiency and reduce cardiovascular risk. Clinical results prior to acquisition showed promise in these areas but no commercial product reached the market before the company was acquired by MedImmune/AstraZeneca[1][2][3].
- Therapeutic areas
- CardiovascularRare Diseases
- Modalities
- Recombinant protein therapeutics (specifically recombinant human LCAT)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Acquired by MedImmune/AstraZeneca; no other major partnerships reported[2].
Beyond the preview
Go deeper on AlphaCore Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlphaCore Pharma.